DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DBD - US2536512021 - Common Stock
64.99 USD
+0.47 (+0.73%)
64.99 USD
0 (0%)
Overall DBD gets a fundamental rating of 4 out of 10. We evaluated DBD against 35 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has an average financial health and profitability rating. DBD is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
DBD had positive earnings in the past year.
DBD had a positive operating cash flow in the past year.
DBD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of 1.36%, DBD perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
The Return On Equity of DBD (4.57%) is better than 71.43% of its industry peers.
DBD's Return On Invested Capital of 8.85% is fine compared to the rest of the industry. DBD outperforms 71.43% of its industry peers.
DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 15.32%.
The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.85%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
DBD's Profit Margin of 1.37% is in line compared to the rest of the industry. DBD outperforms 60.00% of its industry peers.
DBD's Operating Margin of 7.47% is fine compared to the rest of the industry. DBD outperforms 77.14% of its industry peers.
DBD's Operating Margin has improved in the last couple of years.
DBD has a worse Gross Margin (25.48%) than 60.00% of its industry peers.
DBD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
Compared to 1 year ago, DBD has about the same amount of shares outstanding.
The number of shares outstanding for DBD has been reduced compared to 5 years ago.
The debt/assets ratio for DBD has been reduced compared to a year ago.
2.2 Solvency
DBD has an Altman-Z score of 1.93. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.93, DBD is in line with its industry, outperforming 51.43% of the companies in the same industry.
DBD has a debt to FCF ratio of 3.71. This is a good value and a sign of high solvency as DBD would need 3.71 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.71, DBD is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
A Debt/Equity ratio of 0.84 indicates that DBD is somewhat dependend on debt financing.
DBD has a worse Debt to Equity ratio (0.84) than 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.93 |
ROIC/WACC0.95
WACC9.31%
2.3 Liquidity
DBD has a Current Ratio of 1.36. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of DBD (1.36) is comparable to the rest of the industry.
DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
DBD has a Quick ratio of 0.89. This is comparable to the rest of the industry: DBD outperforms 54.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The earnings per share for DBD have decreased strongly by -38.07% in the last year.
Measured over the past years, DBD shows a very strong growth in Earnings Per Share. The EPS has been growing by 69.69% on average per year.
Looking at the last year, DBD shows a decrease in Revenue. The Revenue has decreased by -2.86% in the last year.
Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.18% on average per year.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
DBD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.87% yearly.
The Revenue is expected to grow by 2.83% on average over the next years.
EPS Next Y-3.97%
EPS Next 2Y13.81%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue Next Year2.09%
Revenue Next 2Y2.32%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
DBD is valuated rather expensively with a Price/Earnings ratio of 17.76.
DBD's Price/Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 77.14% of the companies in the same industry.
DBD's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.31.
The Price/Forward Earnings ratio is 13.00, which indicates a correct valuation of DBD.
65.71% of the companies in the same industry are more expensive than DBD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.56, DBD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.76 | ||
| Fwd PE | 13 |
4.2 Price Multiples
94.29% of the companies in the same industry are more expensive than DBD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, DBD is valued cheaper than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.27 | ||
| EV/EBITDA | 7.23 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.81%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
64.99
+0.47 (+0.73%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.22%
Inst Owner Change-2.66%
Ins Owners1.78%
Ins Owner Change0%
Market Cap2.33B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target80.58 (23.99%)
Short Float %2.35%
Short Ratio4.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)4.41%
PT rev (3m)4.41%
EPS NQ rev (1m)8.72%
EPS NQ rev (3m)11.47%
EPS NY rev (1m)-0.41%
EPS NY rev (3m)6.07%
Revenue NQ rev (1m)-0.97%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.76 | ||
| Fwd PE | 13 | ||
| P/S | 0.63 | ||
| P/FCF | 9.27 | ||
| P/OCF | 8.34 | ||
| P/B | 2.11 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.23 |
EPS(TTM)3.66
EY5.63%
EPS(NY)5
Fwd EY7.69%
FCF(TTM)7.01
FCFY10.79%
OCF(TTM)7.79
OCFY11.99%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)N/A
PEG (5Y)N/A
Graham Number50.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.93 |
F-Score7
WACC9.31%
ROIC/WACC0.95
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y-3.97%
EPS Next 2Y13.81%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year2.09%
Revenue Next 2Y2.32%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.77%
EBIT Next 3Y13.69%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
What is the valuation status for DBD stock?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 4 / 10.
How financially healthy is DIEBOLD NIXDORF INC?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.
Can you provide the dividend sustainability for DBD stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.